MCID: PSY004
MIFTS: 67

Psychotic Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Psychotic Disorder

MalaCards integrated aliases for Psychotic Disorder:

Name: Psychotic Disorder 12 14
Psychotic Disorders 41 69
Mental or Behavioural Disorder 12
Mental Disorders 69
Psychotic 52

Classifications:

ICD10: 33


Summaries for Psychotic Disorder

MedlinePlus : 41 psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. people with psychoses lose touch with reality. two of the main symptoms are delusions and hallucinations. delusions are false beliefs, such as thinking that someone is plotting against you or that the tv is sending you secret messages. hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there. schizophrenia is one type of psychotic disorder. people with bipolar disorder may also have psychotic symptoms. other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke. treatment depends on the cause of the psychosis. it might involve drugs to control symptoms and talk therapy. hospitalization is an option for serious cases where a person might be dangerous to himself or others.

MalaCards based summary : Psychotic Disorder, also known as psychotic disorders, is related to schizophrenia 9 and schizophrenia, and has symptoms including alexithymia, decreased libido and increased libido. An important gene associated with Psychotic Disorder is DISC1 (Disrupted In Schizophrenia 1), and among its related pathways/superpathways are Neuroscience and Circadian rythm related genes. The drugs Aripiprazole and Asenapine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and behavior/neurological

Disease Ontology : 12 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality.

Related Diseases for Psychotic Disorder

Diseases related to Psychotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 9 32.4 DISC1 RGS4
2 schizophrenia 29.5 BDNF COMT DAOA DISC1 DRD2 DRD3
3 personality disorder 28.8 BDNF COMT DISC1 DRD2 DRD3 DRD4
4 schizophreniform disorder 11.6
5 schizoaffective disorder 11.0
6 delusional disorder 11.0
7 drug psychosis 10.9
8 familial partial lipodystrophy 10.8 DISC1 SHANK3 SLC6A4
9 ornithosis 10.8 DRD2 PRL SLC6A4
10 chronic dacryoadenitis 10.8 BDNF COMT PRL SLC6A4
11 anosognosia 10.8 COMT DRD2 SLC6A4
12 strabismus 10.8 DRD2 PRL S100B
13 splenic abscess 10.8 DRD2 HTR2A SLC6A4
14 acquired aneurysmal subarachnoid hemorrhage 10.8 HTR2A MAOB SLC6A4
15 conjunctival pigmentation 10.8 MAOB SLC6A4
16 hyperthyroxinemia 10.7 DRD2 HTR2A SLC6A4
17 hypertrichosis lanuginosa congenita 10.7 COMT PRODH
18 pompholyx 10.7 DRD2 HTR2A SLC6A4
19 tongue disease 10.7 COMT DRD2 MAOB SLC6A4
20 intrahepatic gall duct cancer 10.7 BDNF COMT HTR2A SLC6A4
21 ovarian cystadenocarcinoma 10.7 BDNF MAOB SLC18A2
22 obsessive-compulsive personality disorder 10.7 BDNF COMT HTR2A SLC6A4
23 atypical autism 10.7 BDNF SHANK3 SLC6A4
24 hypoglycemic coma 10.7 BDNF HTR2A SLC6A4
25 ulcerative colitis 10.7 BDNF COMT DRD2 S100B
26 bladder hepatoid adenocarcinoma 10.7 DRD2 PRL SLC18A2 SLC6A4
27 keratosis 10.7 BDNF COMT HTR2A SLC6A4
28 brain meningioma 10.7 BDNF COMT DRD2 S100B
29 perinatal necrotizing enterocolitis 10.7 BDNF COMT DRD2 SLC6A4
30 chagas disease 10.7 BDNF COMT HTR2A SLC6A4
31 adrenal gland pheochromocytoma 10.7 COMT MAOB SLC18A2
32 dissociative disorder 10.7 DRD3 SLC6A4
33 eosinophilia-myalgia syndrome 10.7 BDNF DRD2 DRD4
34 rhinoscleroma 10.7 COMT DRD2 NRG1 PRL
35 mental retardation, x-linked, syndromic 13 10.7
36 schizophrenia 17 10.7
37 schizophrenia susceptibility 18 10.7
38 schizophrenia 4 10.7
39 schizophrenia 15 10.7
40 c8 deficiency, type ii 10.7 COMT DRD2 DRD4
41 suppurative periapical periodontitis 10.7 DRD2 DRD3 SLC6A4
42 pervasive developmental disorder 10.7 BDNF COMT DRD4 SLC6A4
43 hemorrhagic cystitis 10.7 COMT DRD2 DRD4 SLC6A4
44 postencephalitic parkinson disease 10.6 BDNF DRD2 HTR2A SLC6A4
45 laryngeal adductor paralysis 10.6 DRD4 HTR2A SLC6A4
46 placenta disease 10.6 DRD2 DRD3 DRD4
47 acute female pelvic peritonitis 10.6 DRD2 DRD3 PRL SLC6A4
48 antisocial personality disorder 10.6 DRD2 DRD3 DRD4
49 carotid stenosis 10.6 COMT DRD2 DRD4 SLC6A4
50 intracranial cavernous angioma 10.6 DRD2 SLC6A4

Graphical network of the top 20 diseases related to Psychotic Disorder:



Diseases related to Psychotic Disorder

Symptoms & Phenotypes for Psychotic Disorder

UMLS symptoms related to Psychotic Disorder:


alexithymia, decreased libido, increased libido, lethargy, nervousness, numbness, agitation, psychiatric symptom, hallucinations, auditory, hallucinations, visual, reduced consciousness/confusion, numbness localized, feeling detached, feeling strange, feeling weightless, floating feeling, dejection emotional, depressed reaction, hallucinations, sensory, restless sleep, difficulty sleeping, excitability, depression aggravated, agitation mental, numb mouth, forgetful, feeling jittery, opiate withdrawal symptoms, clouded consciousness, trembling inside, sluggishness, symptoms, fatigue, sleep disturbances, photophobia, mental and behavioral signs and symptoms, personality changes, catatonic reaction, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Psychotic Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.36 PRODH
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.36 PRODH
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.36 PRODH
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.36 PRODH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.36 DRD3 PRODH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.36 DRD3 DRD4 PRODH
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.36 PRODH
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.36 PRODH

MGI Mouse Phenotypes related to Psychotic Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 SHANK3 SLC18A2 SLC1A1 SLC6A4 BDNF COMT
2 homeostasis/metabolism MP:0005376 10.22 RGS4 S100B SHANK3 SLC18A2 SLC1A1 SLC6A4
3 nervous system MP:0003631 10.03 BDNF COMT DISC1 DRD2 DRD3 DRD4
4 integument MP:0010771 9.91 BDNF DRD2 DTNBP1 PRL PRODH RGS4
5 renal/urinary system MP:0005367 9.5 COMT DRD2 DRD3 DTNBP1 MAOB RGS4
6 taste/olfaction MP:0005394 8.92 BDNF DRD2 SHANK3 SLC18A2

Drugs & Therapeutics for Psychotic Disorder

Drugs for Psychotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1038)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Sulpiride Approved Phase 4,Phase 3,Phase 2,Phase 1 15676-16-1 5355
5
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1 52-86-8 3559
6
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
7
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 298-46-4 2554
8
Coal tar Approved Phase 4,Phase 2 8007-45-2
9
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
10
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
11
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
12
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1 146939-27-7 60854
13
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
14
Zolpidem Approved Phase 4,Phase 3,Phase 2,Phase 1 82626-48-0 5732
15 Zotepine Approved Phase 4 26615-21-4
16
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
17
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
18
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
19
Chlorpromazine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-53-3 2726
20
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 249296-44-4 5310966
21
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 112111-43-0
22
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 68693-11-8 4236
23
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
24
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 29110-47-2 3519
25
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 5786-21-0 2818
26
Etomidate Approved Phase 4 33125-97-2 36339 667484
27
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 2078-54-8 4943
28
Moxonidine Approved Phase 4 75438-57-2 4810
29
Reboxetine Approved, Investigational Phase 4,Phase 2,Phase 1 98769-81-4, 71620-89-8 123628 65856
30
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 10118-90-8 5281021
31
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-41-2 439260
32
Carbidopa Approved Phase 4,Phase 2,Phase 3,Phase 1 28860-95-9 34359 38101
33
Levodopa Approved Phase 4,Phase 2,Phase 3,Phase 1 59-92-7 6047
34
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
35
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
36
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 148553-50-8 5486971
37
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 54-11-5 942 89594
38
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 28981-97-7 2118
39
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
40
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
41
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1972-08-3 16078 2978
42
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
43
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
44
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
45
Amphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 300-62-9 5826 3007
46
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
47
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
48
Trazodone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19794-93-5 5533
49
Diazepam Approved, Illicit, Vet_approved Phase 4,Early Phase 1 439-14-5 3016
50
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 2 54739-18-3 3404 5324346

Interventional clinical trials:

(show top 50) (show all 10000)

id Name Status NCT ID Phase Drugs
1 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
2 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
3 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4 Asenapine
4 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
5 Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) Unknown status NCT01822418 Phase 4 agomelatine
6 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
7 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
8 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
9 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
10 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
11 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
12 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
13 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
14 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
15 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
16 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
17 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
18 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
19 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
20 Varenicline Adjunctive Treatment in Schizophrenia Unknown status NCT00492349 Phase 4 Varenicline;Placebo
21 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
22 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
23 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
24 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
25 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
26 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4 Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole;Tandospirone
27 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4 Moxonidine;Placebo;Moxonidine;Placebo
28 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
29 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
30 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
31 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
32 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4 Risperidone;Paliperidone
33 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
34 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
35 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
36 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
37 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
38 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4 Risperidone, Haloperidol
39 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg)
40 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4 Intrinsa Transdermal testosterone patch
41 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
42 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
43 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
44 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Unknown status NCT00802919 Phase 4 Varenicline;Placebo for varenicline
45 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
46 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
47 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
48 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
49 Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure Unknown status NCT00633685 Phase 4 Fluoxetine;Placebo
50 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4 Varenicline;Placebo

Search NIH Clinical Center for Psychotic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Psychotic Disorder

Anatomical Context for Psychotic Disorder

MalaCards organs/tissues related to Psychotic Disorder:

39
Brain, Testes, Heart, Eye, Cortex, Prefrontal Cortex, Bone

Publications for Psychotic Disorder

Articles related to Psychotic Disorder:

(show top 50) (show all 369)
id Title Authors Year
1
Abnormal frontoparietal synaptic gain mediating the P300 in patients with psychotic disorder and their unaffected relatives. ( 28345275 )
2017
2
Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience. ( 28436345 )
2017
3
Cognitive changes in alcohol-induced psychotic disorder. ( 28446210 )
2017
4
Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort. ( 28949339 )
2017
5
The details of structural disconnectivity in psychotic disorder: A family-based study of non-FA diffusion weighted imaging measures. ( 28709907 )
2017
6
Auditory hallucinations, not necessarily a hallmark of psychotic disorder. ( 28826411 )
2017
7
Emergence of new-onset psychotic disorder following recovery from LGI1 antibody-associated limbic encephalitis. ( 28363946 )
2017
8
Higher required dosage of antipsychotics to relieve the symptoms of first-onset Acute and Transient Psychotic Disorder (ATPD) predicted the subsequent diagnostic transition to schizophrenia: A longitudinal study. ( 28739289 )
2017
9
Exploring the use of Routine Outcome Monitoring in the treatment of patients with a psychotic disorder. ( 28314165 )
2017
10
Antipsychotic treatment and the Rorschach Perceptual Thinking Index (PTI) in psychotic disorder patients: Effects of treatment. ( 28236781 )
2017
11
Outcome of first-episode acute and transient psychotic disorder in Hong Kong Chinese: a 20-year retrospective follow-up study. ( 27834101 )
2017
12
Correction: No Evidence of Association between Childhood Urban Environment and Cortical Thinning in Psychotic Disorder. ( 28542397 )
2017
13
No Evidence of Association between Childhood Urban Environment and Cortical Thinning in Psychotic Disorder. ( 28045900 )
2017
14
Evidence That the Impact of Childhood Trauma on IQ Is Substantial in Controls, Moderate in Siblings, and Absent in Patients With Psychotic Disorder. ( 28177077 )
2017
15
Clozapine Safety and Efficacy for Interictal Psychotic Disorder in Pharmacoresistant Epilepsy. ( 28632525 )
2017
16
A case report of brief psychotic disorder with catalepsy associated with sequential life-threatening events in a patient with advanced cancer. ( 28413438 )
2017
17
GRIN3B missense mutation as an inherited risk factor for schizophrenia: whole-exome sequencing in a family with a familiar history of psychotic disorders. ( 28132660 )
2017
18
Diagnostic validity of ICD-10 acute and transient psychotic disorders and DSM-5 brief psychotic disorder. ( 28756108 )
2017
19
Serum S100B: A proxy marker for grey and white matter status in the absence and presence of (increased risk of) psychotic disorder? ( 28358925 )
2017
20
Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study. ( 28464965 )
2017
21
Ethnic differences in physician follow-up after a first diagnosis of psychotic disorder. ( 28709775 )
2017
22
Outcome of acute and transient psychotic disorder in an index episode: A study from a tertiary care centre in North India. ( 28262127 )
2017
23
Anti-NMDA receptor encephalitis presenting as a primary psychotic disorder. ( 28738102 )
2017
24
Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder. ( 28648915 )
2017
25
Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. ( 28517032 )
2017
26
Clinical consequences of extensive routine laboratory investigations in patients with a recent onset psychotic disorder. ( 28162811 )
2017
27
Quantitative exploration of factors influencing psychotic disorder ailments in Nigeria. ( 28795095 )
2017
28
Dopamine D2-receptor affinity of antipsychotics in relation to subjective well-being in patients with a psychotic disorder. ( 28542034 )
2017
29
Insight in body dysmorphic disorder (BDD) relative to obsessive-compulsive disorder (OCD) and psychotic disorders: Revisiting this issue in light of DSM-5. ( 28651226 )
2017
30
Does the Social Functioning Scale reflect real-life social functioning? An experience sampling study in patients with a non-affective psychotic disorder and healthy control individuals. ( 28534464 )
2017
31
Short-term outcome of substance-induced psychotic disorder in a large UK first episode psychosis cohort. ( 27479903 )
2016
32
Acute polymorphic psychotic disorder: Differences from other acute and transient psychoses. ( 26871426 )
2016
33
Porencephalic cyst and late onset brief psychotic disorder. ( 27053544 )
2016
34
Differential Time Course of Microstructural White Matter in Patients With Psychotic Disorder and Individuals at Risk: A 3-Year Follow-up Study. ( 27190279 )
2016
35
Association study of GABA system genes polymorphisms with amphetamine-induced psychotic disorder in a Han Chinese population. ( 27080428 )
2016
36
Cognitive Performance and Long-Term Social Functioning in Psychotic Disorder: A Three-Year Follow-Up Study. ( 27082629 )
2016
37
Misdiagnosis of cerebral malaria initially as acute psychotic disorder and later as human rabies: a case report. ( 27514689 )
2016
38
Do routine outcome monitoring results translate to clinical practice? A cross-sectional study in patients with a psychotic disorder. ( 27091333 )
2016
39
Effect of virtual reality exposure therapy on social participation in people with a psychotic disorder (VRETp): study protocol for a randomized controlled trial. ( 26762123 )
2016
40
Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. ( 27828960 )
2016
41
BEATVIC, a body-oriented resilience training with elements of kickboxing for individuals with a psychotic disorder: study protocol of a multi-center RCT. ( 27393604 )
2016
42
Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? ( 27650124 )
2016
43
Life-threatening ketoacidosis in a pregnant woman with psychotic disorder. ( 27512491 )
2016
44
Bullying victimisation increases the risk of emergence and persistence of specific psychotic symptoms and of psychotic disorder. ( 26718965 )
2016
45
Social functioning in patients with a psychotic disorder and first rank symptoms. ( 26892072 )
2016
46
Indomethacin-Induced Psychotic Disorder. ( 27046657 )
2016
47
Comparing the experience of voices in borderline personality disorder with the experience of voices in a psychotic disorder: A systematic review. ( 26912339 )
2016
48
Resilience in patients with psychotic disorder. ( 27110878 )
2016
49
Psychotic disorder associated with 22q11.2 duplication syndrome. ( 26763109 )
2016
50
Self-Reported Reasons for Smoking: Predicting Abstinence and Implications for Smoking Cessation Treatments Among Those With a Psychotic Disorder. ( 27982748 )
2016

Variations for Psychotic Disorder

Expression for Psychotic Disorder

Search GEO for disease gene expression data for Psychotic Disorder.

Pathways for Psychotic Disorder

Pathways related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1 12.31 COMT DTNBP1 RGS4 S100B SLC1A1
3
Show member pathways
11.89 COMT DRD2 DRD3 DRD4 MAOB SHANK3
4
Show member pathways
11.74 BDNF DRD2 MAOB SLC18A2
5
Show member pathways
11.73 NRG1 PRL S100B
6 11.69 DRD3 DRD4 HTR2A
7
Show member pathways
11.68 DRD2 DRD3 DRD4 HTR2A
8 11.61 HTR2A MAOB SLC18A2 SLC6A4
9 11.54 BDNF S100B SLC18A2
10
Show member pathways
11.27 DRD2 DRD3 DRD4 SLC18A2
11 10.78 HTR2A SLC18A2 SLC6A4
12 10.64 COMT MAOB
13
Show member pathways
10.62 COMT MAOB

GO Terms for Psychotic Disorder

Cellular components related to Psychotic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 postsynaptic membrane GO:0045211 9.67 COMT DISC1 DTNBP1 SHANK3
2 postsynaptic density GO:0014069 9.62 DISC1 DRD2 DTNBP1 SHANK3
3 integral component of plasma membrane GO:0005887 9.61 DRD2 DRD3 DRD4 FXYD6 HTR2A NRG1
4 cell body GO:0044297 9.58 COMT DISC1 NRG1
5 dendritic spine GO:0043197 9.56 COMT DRD2 DTNBP1 SHANK3
6 axon GO:0030424 9.1 COMT DISC1 DRD2 DTNBP1 HTR2A NRG1
7 plasma membrane GO:0005886 10 COMT DISC1 DRD2 DRD3 DRD4 DTNBP1

Biological processes related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 40)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.93 COMT DRD2 DRD3 HTR2A MAOB SLC6A4
2 response to toxic substance GO:0009636 9.86 DRD2 MAOB SLC18A2 SLC6A4
3 cellular calcium ion homeostasis GO:0006874 9.84 DRD3 DRD4 HTR2A
4 learning GO:0007612 9.8 COMT DRD3 SHANK3
5 memory GO:0007613 9.8 HTR2A S100B SHANK3 SLC6A4
6 learning or memory GO:0007611 9.79 DRD3 S100B SHANK3
7 synapse assembly GO:0007416 9.78 BDNF DRD2 NRG1 SHANK3
8 negative regulation of adenylate cyclase activity GO:0007194 9.77 DRD2 DRD3 DRD4
9 locomotory behavior GO:0007626 9.77 DRD2 DRD3 NRG1 SHANK3 SLC18A2
10 arachidonic acid secretion GO:0050482 9.71 DRD2 DRD3 DRD4
11 social behavior GO:0035176 9.71 DRD3 DRD4 SHANK3 SLC6A4
12 dopamine receptor signaling pathway GO:0007212 9.7 DRD2 DRD3 DRD4
13 negative regulation of protein secretion GO:0050709 9.69 DRD2 DRD3 DRD4
14 synaptic transmission, dopaminergic GO:0001963 9.68 DRD2 DRD3
15 positive regulation of long-term synaptic potentiation GO:1900273 9.68 DRD2 SHANK3
16 behavioral response to ethanol GO:0048149 9.68 DRD2 DRD4
17 positive regulation of kinase activity GO:0033674 9.67 DRD4 HTR2A
18 startle response GO:0001964 9.67 DRD2 NRG1
19 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.67 DRD2 HTR2A
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.66 DRD2 DRD4
21 prepulse inhibition GO:0060134 9.65 DRD2 DRD3
22 positive regulation of renal sodium excretion GO:0035815 9.65 DRD2 DRD3
23 G-protein coupled receptor internalization GO:0002031 9.64 DRD2 DRD3
24 neurotransmitter catabolic process GO:0042135 9.64 COMT MAOB
25 monoamine transport GO:0015844 9.63 SLC18A2 SLC6A4
26 dopamine catabolic process GO:0042420 9.63 COMT MAOB
27 response to amphetamine GO:0001975 9.62 DRD2 DRD3 DRD4 SLC18A2
28 regulation of cAMP metabolic process GO:0030814 9.61 DRD2 DRD3
29 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.61 DRD2 DRD3
30 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD2 DRD3 DRD4
31 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.59 DRD2 DRD4
32 negative regulation of dopamine receptor signaling pathway GO:0060160 9.58 DRD2 DRD3
33 serotonin transport GO:0006837 9.58 SLC18A2 SLC6A4
34 acid secretion GO:0046717 9.57 DRD2 DRD3
35 regulation of dopamine secretion GO:0014059 9.56 DRD2 DRD3 DTNBP1 HTR2A
36 regulation of locomotion involved in locomotory behavior GO:0090325 9.55 DRD2 DRD3
37 behavioral response to cocaine GO:0048148 9.46 DRD2 DRD3 DRD4 HTR2A
38 positive regulation of myelination GO:0031643 9.35 NRG1
39 response to histamine GO